MANERIX 300 MG
MOCLOBEMIDE : 300 MG · DIN 02166747 · BAUSCH HEALTH, CANADA INC.
Health Canada status: MARKETED
What is MANERIX?
MANERIX 300 MG contains MOCLOBEMIDE : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 02166747, held by BAUSCH HEALTH, CANADA INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 24-Jun-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MANERIX used for?
MANERIX (moclobemide) is indicated for the treatment of major depressive disorder (MDD) in adults.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is MANERIX called?
The same molecule, MOCLOBEMIDE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Aurorix | Latin | Australia, South Africa |
| Clobemix | Latin | Australia |
| Moclobemide Sandoz | Latin | Australia |
| MOCLOBEMIDE-WGR | Latin | Australia |
| Depnil | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02166747 |
|---|---|
| Brand name | MANERIX |
| Generic / active ingredient | MOCLOBEMIDE : 300 MG |
| Manufacturer | BAUSCH HEALTH, CANADA INC. |
| Strength | 300 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AG02 MOCLOBEMIDE |
| AHFS class | 28:16.04.12 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 24-Jun-2021 |
| Original market date | 1995-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02166747 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2166747 |
| Brand name | MANERIX |
| Active ingredient / INN | MOCLOBEMIDE : 300 MG |
| ATC code | N06AG02 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N06 |
| AHFS class | 28:16.04.12 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | BAUSCH HEALTH, CANADA INC. |
How is it stored and handled?
null
How is it supplied?
cartons of 60 (6x 10 blister packs) tablets
Which pack is which?
| Strength on the label | 300 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Packaging as described in the monograph | cartons of 60 (6x 10 blister packs) tablets |
| Storage | null |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code N06AG02 MOCLOBEMIDE. 4 of 21 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MOCLOBEMIDE | 100 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02232148 |
| MOCLOBEMIDE | 150 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02232150 |
| MOCLOBEMIDE | 300 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02240456 |
| DOM-MOCLOBEMIDE TABLETS 150MG | 150 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02243348 |
| DOM-MOCLOBEMIDE TABLETS 300MG | 300 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02243349 |
| MANERIX | 150 MG | TABLET | BAUSCH HEALTH, CANADA INC. | DORMANT | DIN 00899356 |
| MANERIX TAB 100MG | 100 MG | TABLET | HOFFMANN-LA ROCHE LIMITED | CANCELLED POST MARKET | DIN 00899348 |
| MOCLOBEMIDE-100 | 100 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 02236928 |
| MOCLOBEMIDE-150 | 150 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 02236929 |
| NU-MOCLOBEMIDE | 100 MG | TABLET | NU-PHARM INC | CANCELLED POST MARKET | DIN 02237111 |
Who else supplies MOCLOBEMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MOCLOBEMIDE appears in 119 registered pack listings across 6 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does MOCLOBEMIDE cost around the world?
MOCLOBEMIDE is listed on 4 national price registers Nexara tracks, across 31 pack listings published on 4 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Australia | ex-manufacturer | 7 | 20 | 08 Sep 2026 |
| South Africa | single exit price | 5 | 6 | 01 Sep 2026 |
| Saudi Arabia | public | 2 | 4 | 01 Sep 2026 |
| United Kingdom | hospital | 1 | 1 | 31 Aug 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.